Free Trial

Check-Cap Q3 2023 Earnings Report

Check-Cap logo
$0.78 -0.01 (-1.27%)
As of 11:37 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Check-Cap EPS Results

Actual EPS
-$0.44
Consensus EPS
-$0.83
Beat/Miss
Beat by +$0.39
One Year Ago EPS
N/A

Check-Cap Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Check-Cap Announcement Details

Quarter
Q3 2023
Time
Q3 2023 Earnings Release

Conference Call Resources

Remove Ads

Check-Cap Earnings Headlines

Check-Cap Leads 3 US Penny Stocks To Monitor
Your Wealth is Under Attack
Please don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your free gift, and see how Trump's victory could spark major gains for gold.
See More Check-Cap Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Check-Cap? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Check-Cap and other key companies, straight to your email.

About Check-Cap

Check-Cap (NASDAQ:CHEK), a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.

View Check-Cap Profile

More Earnings Resources from MarketBeat